Financial Releases

Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms CHASKA, Minn. , Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc.

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn. , Jan. 07, 2025 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development

CHASKA, Minn. , Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43 rd Annual J.P. Morgan Healthcare Conference .

-- Recorded Revenues of $32.6 Million   for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3 Million , and Favorable Restructuring of Credit Facility with BMO -- Conference Call Today at 4:30pm